Mucocutaneous paraneoplastic syndromes associated with hematologic malignancies

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Cutaneous paraneoplastic syndromes (CPS) are skin manifestations linked to underlying cancers, often improving with malignancy treatment.
• Paraneoplastic pemphigus (PNP) is a rare, distinct CPS associated with lymphocytic neoplasms, characterized by severe mucosal and cutaneous lesions.
• PNP exhibits unique antibody-mediated attacks on non-squamous epithelium and has a high mortality rate, exceeding 90% in malignant cases.

Observation:

• A case report details a 39-year-old male with grade 3 follicular lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who developed PNP.
• This presentation highlights a diagnostic and treatment challenge, as PNP can occur even during or after chemotherapy.
• Pulmonary involvement affects 30-40% of PNP patients, underscoring the systemic nature of the disease.

Findings:

• Paraneoplastic pemphigus (PNP) is a rare autoimmune blistering disease.
• PNP is strongly associated with lymphocytic neoplasms.
• The high mortality rate and lack of established treatment guidelines for PNP present significant clinical challenges.

Implications:

• Effective management strategies for PNP, particularly in the context of hematologic malignancies, require further investigation.
• This case underscores the complexity of managing autoimmune conditions that arise during cancer therapy.
• Understanding the pathogenesis of PNP is crucial for developing targeted therapies and improving patient outcomes.